Key Points
- Nano-tech mitragynine is a delivery formulation, not a new alkaloid. Manufacturers use terms such as “Nano Tech” to describe processing intended to improve how mitragynine disperses or is absorbed.
- Faster absorption claims remain largely unverified for commercial products. Nanotechnology has been studied in experimental mitragynine formulations, but published research does not establish that commercially available nano-tech tablets work faster or are safer than conventional extracts.
- 7Stax is one company marketing nano-tech mitragynine tablets. Its product listings advertise chewable tablets containing 80 mg or 120 mg of mitragynine, with claims of improved absorption.
- Independent testing has raised ingredient concerns. A March 2026 laboratory report for a 7Stax Nano Tech tablet labeled as containing 80 mg of mitragynine identified approximately 23.10 mg of mitragynine and 17.64 mg of MGM-15, a potent synthetic opioid.
- Mitragynine can cause dependence. Concentrated products can contribute to tolerance, withdrawal, cravings, and other substance-related complications, particularly with repeated use.
- How Brooks Helps: Brooks Healing Center provides medically supervised detox, residential addiction treatment, medication assessments, and ongoing recovery support for people struggling with kratom, 7-OH, and other opioid-active substances.
Kratom products have changed considerably from the loose powders, capsules, and teas that dominated the market a few years ago. Today, manufacturers are selling concentrated alkaloids in chewable tablets, flavored shots, and products advertised as having enhanced absorption.
One of the newer terms appearing on packaging is “nano-tech mitragynine.”
The idea sounds relatively simple. Take mitragynine, the primary psychoactive alkaloid in kratom, process it into smaller particles, and market the resulting formulation as faster-acting or more efficient than conventional kratom products.
But there are questions worth asking before accepting those claims. Does nano-technology actually make mitragynine stronger? Can it increase dependence or withdrawal risk? And how can consumers know whether the amount listed on a tablet’s packaging reflects what is inside?
Those questions became particularly important after independent laboratory testing of a submitted 7Stax Nano Tech tablet identified substantially less mitragynine than advertised, along with an undisclosed opioid compound called MGM-15.
Understanding these findings requires separating the science of drug delivery from the marketing surrounding these products.
What Is Nano-Tech Mitragynine?
Nano-tech mitragynine generally refers to mitragynine products manufactured using techniques intended to alter particle size, dispersion, or other properties affecting how a substance is delivered.
Mitragynine itself is not a new chemical. It is the most abundant psychoactive alkaloid found in Mitragyna speciosa, the Southeast Asian tree commonly known as kratom.
Researchers have studied mitragynine for its effects on opioid receptors and other biological systems. Unlike 7-hydroxymitragynine, commonly called 7-OH, mitragynine generally demonstrates a different opioid-receptor activity profile.
The body can also metabolize some mitragynine into 7-OH, which contributes to the complexity of its pharmacology.
What makes nano-tech products different is the advertised manufacturing process rather than the identity of mitragynine itself.
What Does “Nano Tech” Mean on a Kratom Product?
Nanotechnology involves engineering or manipulating materials at extremely small scales. In pharmaceutical research, nanoscale drug-delivery systems can sometimes improve how poorly soluble compounds dissolve, disperse, or reach their intended biological targets.
For substances with limited water solubility, formulation changes may influence absorption and exposure.
However, there is an important difference between a scientifically characterized nanoparticle formulation and a product simply using the word “nano” in its marketing.
A company might use mechanical particle-size reduction, specialized dispersing agents, or other manufacturing techniques without necessarily producing a true nanoscale delivery system.
For example, 7Stax describes its Nano Tech process as particle-size reduction intended to improve dispersion and consistency. The company states that Nano Tech does not refer to another active ingredient or a proprietary chemical blend.
That description is a manufacturer claim, not independent evidence that every product contains particles within a particular nanoscale range or achieves greater absorption in humans.
How Does Nano-Tech Mitragynine Work?
The proposed benefit of nano-tech mitragynine is improved delivery of the active compound.
When someone consumes a conventional kratom extract, several factors influence how much mitragynine enters the bloodstream. These include the product’s chemical composition, dissolution characteristics, digestive conditions, metabolism, and the individual’s physiology.
Researchers have investigated whether alternative formulations could change these processes.
A 2025 scientific review by Sarker and Nahar examined experimental delivery systems for mitragynine, including nanotechnology-based approaches.
The researchers discussed how specialized formulations may improve certain delivery characteristics. However, the research does not establish that every commercially advertised nano-tech kratom product provides those benefits.
Could Smaller Particles Increase Absorption?
In principle, reducing particle size can increase the surface area available for dissolution. For some poorly soluble compounds, that may improve the rate at which the substance dissolves.
But improved dissolution is not automatically the same as greater absorption into the bloodstream.
The actual effect depends on the formulation, particle characteristics, chemical stability, and biological conditions.
To demonstrate superior absorption in humans, manufacturers would need appropriate comparative pharmacokinetic testing.
Such testing could measure:
- How quickly mitragynine reaches the bloodstream
- The maximum blood concentration achieved
- Total drug exposure over time
- Differences compared with a conventional formulation
- Variability between individuals
- Whether the formulation changes exposure to active metabolites
Without that evidence, advertising claims about faster onset or superior bioavailability remain unverified for the particular product.
Does Nano-Tech Make Mitragynine Stronger?
Not necessarily.
Changing how a substance is delivered does not automatically change its intrinsic activity at opioid receptors.
However, if a formulation were demonstrated to increase the amount absorbed or change how rapidly a drug enters circulation, it could potentially change the intensity or timing of its effects.
That possibility deserves careful study, particularly for substances associated with dependence and opioid-like effects.
A delivery system capable of increasing drug exposure is not automatically a safety improvement.
Nano-Tech Mitragynine vs. Regular Kratom vs. 7-OH
Although these products are frequently discussed together, they are not interchangeable.
| Feature | Traditional Kratom | Nano-Tech Mitragynine | Concentrated 7-OH |
|---|---|---|---|
| Primary substance | Whole-leaf alkaloid mixture | Mitragynine, often concentrated | 7-hydroxymitragynine |
| Product type | Powder, capsules, tea | Processed tablets, extracts, or liquids | Concentrated tablets, shots, gummies |
| Opioid activity | Contains opioid-active alkaloids | Mitragynine interacts with opioid receptors | More potent opioid receptor activity |
| Absorption claims | Conventional botanical exposure | Often marketed as enhanced or faster | Varies by formulation |
| Dependence potential | Documented with repeated use | Potential for tolerance and dependence | Significant dependence concerns |
| Main uncertainty | Alkaloid concentration and contamination | Formulation claims, potency, and ingredient verification | Potency, purity, exposure, and overdose risk |
| FDA-approved treatment | No | No | No |
Traditional kratom leaves contain multiple alkaloids, while concentrated products may isolate or substantially increase exposure to selected compounds.
A nano-tech mitragynine product is not automatically a 7-OH product, and mitragynine is not chemically identical to 7-OH.
However, both involve opioid-related pharmacology, and the actual composition of a manufactured tablet matters more than its marketing category.
For a detailed comparison of emerging kratom compounds, see our article on mitragynine pseudoindoxyl vs. 7-OH.
What Are 7Stax Nano Tech Mitragynine Tablets?
7Stax is one of the companies marketing products under the Nano Tech Mitragynine name.
Its product line includes flavored chewable tablets advertised with specific amounts of mitragynine per tablet.
As of November 2026, its website lists formulations advertised as containing 80 mg and 120 mg of mitragynine per tablet.
According to the company’s product descriptions, Nano Tech refers to a particle-size reduction process intended to improve dispersion and consistency.
The products are marketed as convenient, high-strength alternatives to conventional kratom preparations.
However, the company’s claims about faster absorption and dependable onset should be distinguished from evidence obtained through independent human studies.
An even more significant concern involves whether the actual alkaloid contents match what consumers expect.
Independent Testing Found MGM-15 in a 7Stax Nano Tech Tablet
In March 2026, Anresco Laboratories analyzed a 7Stax 80 mg Raspberry Nano Tech tablet submitted through TestMyKratom.org.
The certificate of analysis identified the following substances in the submitted sample:
| Substance | Laboratory Finding |
|---|---|
| Advertised mitragynine | 80 mg per tablet |
| Measured mitragynine | 23.10 mg |
| MGM-15 | 17.64 mg |
| 7-hydroxymitragynine | Not detected |
| Mitragynine pseudoindoxyl | Not detected |
The certificate of analysis was dated March 19, 2026, and identified the tested lot as 2026-03 (sample 1391007).
The findings are concerning for two reasons.
First, the measured mitragynine content was substantially below the advertised amount. The laboratory identified approximately 29% of the stated 80 mg quantity.
Second, the sample contained MGM-15, a manufactured opioid compound with pharmacological properties different from ordinary mitragynine.
MGM-15 was not disclosed as the active ingredient in the product’s mitragynine marketing.
This does not establish that every 7Stax Nano Tech tablet contains MGM-15. The findings apply to the specific sample submitted for analysis, and the laboratory did not independently conduct the retail sampling.
They also do not establish that subsequent formulations or batches have the same composition.
Nevertheless, the report illustrates why product branding, label quantities, and manufacturer descriptions cannot replace comprehensive, independent chemical testing.
Why Is MGM-15 in a Mitragynine Product Concerning?
MGM-15, also known as dihydro-7-hydroxymitragynine, is a chemically modified kratom-derived compound with potent mu-opioid receptor activity.
It is different from ordinary mitragynine and should not be confused with the naturally occurring alkaloid found in kratom leaves.
Animal research has raised serious concerns about its potency, and public health authorities have identified MGM-15 in overdose investigations.
In August 2026, the Drug Enforcement Administration temporarily placed MGM-15 into Schedule I of the Controlled Substances Act.
The presence of an unexpected opioid compound in a product advertised primarily as mitragynine could substantially change its risk profile.
Consumers may believe they are taking a concentrated version of kratom’s main alkaloid while actually receiving a mixture containing another pharmacologically potent substance.
The risks may include unexpectedly strong sedation, respiratory depression, impaired judgment, and greater uncertainty about drug interactions.
Importantly, the Anresco findings do not demonstrate that the Nano Tech manufacturing process created MGM-15. Chemical identity and delivery technology are separate questions.
The laboratory results establish what was detected in the submitted sample, not how the compound entered the product.
Brooks previously examined this substance in our article, MGM-15: What to Know About This New Kratom-Derived Opioid.
Are Nano-Tech Mitragynine Products More Addictive?
There is not enough clinical evidence to conclude that nano-tech mitragynine is inherently more addictive than every conventional mitragynine formulation.
However, concentrated mitragynine exposure can contribute to tolerance, physical dependence, and problematic patterns of use.
Research on kratom has documented dependence and withdrawal among individuals who use it regularly.
Several factors can increase concern:
- Repeated exposure to concentrated alkaloids
- Frequent use throughout the day
- Increasing amounts needed to produce the same effects
- Using the substance primarily to avoid withdrawal
- Combining mitragynine with other opioids or sedatives
- Exposure to unexpected ingredients in manufactured products
If a delivery system increases drug exposure, that change could potentially influence tolerance or adverse effects. The direction and magnitude of that effect would need to be established through research.
For now, claims that nano-tech mitragynine is less addictive because it is more efficiently absorbed are not supported by adequate clinical evidence.
Can Nano-Tech Mitragynine Cause Withdrawal?
Yes. Repeated use of mitragynine-containing products can lead to physical dependence, and discontinuation may produce withdrawal symptoms.
Symptoms associated with kratom withdrawal can include anxiety, restlessness, irritability, sweating, chills, muscle aches, nausea, diarrhea, insomnia, and cravings.
The severity varies considerably between individuals.
A person using traditional kratom occasionally may have a different experience from someone consuming concentrated alkaloid tablets multiple times daily.
Products containing additional opioid-active compounds can further complicate the clinical picture.
There is no validated withdrawal timeline specifically for commercially marketed nano-tech mitragynine formulations.
Individuals experiencing withdrawal can learn more through our guide to 7-OH withdrawal symptoms, timelines, and treatment.
Can Nano-Tech Mitragynine Products Cause an Overdose?
Serious toxicity can occur with kratom-related substances, especially when concentrated products, unexpected ingredients, or multiple depressant drugs are involved.
Mitragynine has a pharmacological profile that differs from conventional full mu-opioid agonists. However, this distinction does not make concentrated mitragynine products harmless.
Potential adverse effects include nausea, dizziness, sedation, confusion, rapid heartbeat, and other neurological or cardiovascular symptoms.
More serious outcomes, including seizures and liver injury, have been reported in association with kratom exposure.
The presence of additional opioid-active substances can create further danger.
For example, an individual consuming a product containing undisclosed MGM-15 might experience effects that would not be expected from the advertised mitragynine content alone.
Combining such products with alcohol, benzodiazepines, prescription opioids, or other sedatives can increase the risk of life-threatening complications.
If someone becomes unresponsive, experiences slowed breathing, or cannot be awakened after taking a kratom-derived product, call 911 immediately.
Administer naloxone if available when opioid toxicity is suspected. Emergency medical evaluation remains essential even if the person responds.
Is Nano-Tech Mitragynine FDA Approved?
No. There are currently no FDA-approved medications containing mitragynine for treating pain, anxiety, depression, opioid withdrawal, or another medical condition.
That includes commercially marketed nano-tech mitragynine formulations.
The FDA has warned about the risks of kratom and concentrated 7-OH products, including dependence, serious adverse events, and concerns surrounding manufacturing and product consistency.
The agency has also distinguished traditional kratom from concentrated 7-OH products that contain substantially elevated amounts of the more potent opioid alkaloid.
In October 2026, federal health officials announced updated recommendations concerning 7-OH and mitragynine pseudoindoxyl. The recommendations were intended to distinguish trace-level botanical exposure from concentrated or intentionally enhanced products.
As of November 3, 2026, the October 14 DEA document is a notice of intent for threshold-based scheduling, not a final order already in effect. It states that a temporary scheduling order may be published on or after November 13, 2026. The earlier August temporary controls on MGM-15 and MGM-16 remain a separate action.
These actions should not be interpreted as FDA approval of concentrated mitragynine tablets.
Is Nano-Tech Mitragynine Legal in Tennessee?
Tennessee enacted a comprehensive kratom prohibition effective July 1, 2026.
The law prohibits the knowing possession, manufacture, sale, and distribution of kratom, including products derived from Mitragyna speciosa containing mitragynine or related covered substances.
Because nano-tech mitragynine products are marketed as containing a kratom-derived alkaloid, their legal status must be evaluated under those restrictions.
A product being sold through an online retailer does not mean it is lawful to possess or distribute in Tennessee.
Laws vary across jurisdictions, and federal scheduling provisions addressing other kratom-derived compounds may apply separately.
For a broader explanation of kratom dependence and treatment in Tennessee, visit our kratom addiction treatment resource.
Is Nano-Tech Mitragynine the Same as MG001?
No. Nano-tech mitragynine products marketed commercially should not be confused with MG001, an investigational pharmaceutical formulation of mitragynine.
In 2026, the National Institutes of Health announced that a mitragynine investigational new drug application had been allowed to proceed, opening the door to controlled human research.
The experimental medication, MG001, is being evaluated through a Phase 1 clinical trial examining safety, tolerability, and pharmacokinetics.
This research is intended to help scientists understand the potential medical applications and limitations of mitragynine.
It does not mean that commercial mitragynine products have been approved as medications or established as effective treatments for opioid withdrawal.
The distinction is important because research involving a defined pharmaceutical formulation does not validate the composition or safety of unrelated retail tablets.
We explore this research in our article, MG001: Could a Kratom-Derived Medication Become a New Treatment for Opioid Withdrawal?.
Can Nano-Tech Mitragynine Help Someone Stop Using 7-OH?
Some consumers may consider switching from concentrated 7-OH products to mitragynine products because they perceive mitragynine as less potent.
However, replacing 7-OH with a concentrated nano-tech formulation is not an established medical treatment for opioid dependence or withdrawal.
Mitragynine still interacts with the opioid system, and repeated use may maintain physical dependence.
Additionally, the actual chemical composition of commercial products may differ from what consumers expect.
The independent 7Stax testing illustrates that concern. A product advertised as containing mitragynine was found to contain another opioid-active substance in one tested sample.
For someone already dependent on concentrated kratom alkaloids, introducing another unapproved product can create new uncertainty rather than resolve the existing problem.
Medical assessment is particularly important when a person experiences significant withdrawal, uses multiple opioid-active substances, or has repeatedly tried to stop without success.
Treatment for Nano-Tech Mitragynine and Kratom Dependence
Someone struggling with dependence on concentrated mitragynine products may find that use gradually becomes part of their daily routine.
What initially began as occasional experimentation or an attempt to manage discomfort can progress into repeated dosing, increasing tolerance, and difficulty functioning without the substance.
For some people, withdrawal becomes the primary reason they continue taking it.
Treatment should begin with a clear understanding of what the person has been using, how frequently they have used it, the ingredients involved when known, and whether other substances are contributing to the situation.
Medical Detox
At Brooks Healing Center, medically supervised detox provides clinical support for patients experiencing substance withdrawal.
Medical professionals can assess symptoms, monitor complications, and develop an individualized stabilization plan.
This may be particularly relevant when someone has been using high-potency kratom extracts, concentrated 7-OH products, or other opioid-active compounds with uncertain formulations.
Medications for Opioid Use Disorder (MOUD)
Brooks also offers medications for opioid use disorder (MOUD) when clinically appropriate.
For individuals diagnosed with opioid use disorder, FDA-approved buprenorphine medications may help manage withdrawal symptoms and cravings while supporting longer-term recovery.
Our options include extended-release injectable buprenorphine medications such as Sublocade and Brixadi.
These medications have established FDA-approved indications for opioid use disorder.
They are not specifically FDA-approved to treat mitragynine or 7-OH dependence, and there is no FDA-approved medication specifically indicated for kratom dependence.
A qualified provider must determine whether medication is appropriate based on the individual’s diagnosis, withdrawal symptoms, exposure history, and medical needs.
Residential Treatment and Continuing Care
For people whose substance use has become difficult to control, residential treatment can provide additional structure and support.
Treatment may address compulsive substance use, cravings, anxiety, depression, trauma, and the behaviors that make returning to use more likely.
Brooks also offers PHP, sober living, and alumni or peer support to help individuals continue recovery beyond initial stabilization.
Frequently Asked Questions About Nano-Tech Mitragynine
What is nano-tech mitragynine?
Nano-tech mitragynine refers to mitragynine formulations marketed as using particle-size reduction or other delivery technologies intended to influence dispersion or absorption. The term does not identify a separate kratom alkaloid or guarantee a scientifically verified nanoparticle formulation.
Does nano-tech mitragynine work faster than regular kratom?
Manufacturers may advertise faster absorption, but published human research has not established a reliable onset advantage for commercially available nano-tech mitragynine products. Experimental delivery research should not be confused with independent verification of a particular retail product.
Are 7Stax Nano Tech tablets the same as 7-OH?
The manufacturer’s Nano Tech product line advertises mitragynine rather than 7-OH as the primary active alkaloid. However, independent testing of one March 2026 sample identified MGM-15. A product’s actual composition depends on its formulation and tested batch.
Was MGM-15 found in 7Stax Nano Tech tablets?
Yes. A March 19, 2026, laboratory report identified 17.64 mg of MGM-15 in a submitted 7Stax 80 mg Raspberry Nano Tech tablet. The same sample contained 23.10 mg of mitragynine rather than the advertised 80 mg. These results should not be generalized to every product or production lot.
Is nano mitragynine more potent than traditional kratom?
Concentrated mitragynine tablets can contain greater quantities of a particular alkaloid than ordinary botanical preparations. However, the word “nano” alone does not establish greater potency or bioavailability. Those properties require product-specific laboratory and clinical evidence.
Can nano-tech mitragynine cause withdrawal?
Yes. Repeated mitragynine exposure can result in physical dependence and withdrawal. Symptoms may include anxiety, sweating, restlessness, insomnia, gastrointestinal discomfort, and cravings. There is no established withdrawal timeline unique to nano-tech products.
Is nano-tech mitragynine legal in Tennessee?
Tennessee prohibits possession, manufacture, and sale of kratom under its July 1, 2026, law, including covered kratom-derived products. Commercial nano-tech mitragynine products should not be assumed legal merely because they are available for purchase online.
Does nano-tech make kratom safer?
There is no reliable clinical evidence establishing that commercially available nano-tech kratom products are safer than traditional formulations. Improved delivery, if demonstrated, would not eliminate dependence, adverse effects, contamination, or unexpected-ingredient risks.
Can nano-tech mitragynine replace Suboxone or other MOUD medications?
No. Commercial nano-tech mitragynine products are not FDA-approved medications for opioid use disorder and have not been established as safe or effective substitutes for buprenorphine-based treatment.
Get Help for Kratom and Mitragynine Dependence at Brooks Healing Center
Nano-tech mitragynine products reflect a broader change in the kratom market. Manufacturers are no longer selling only powders and plant extracts. They are introducing concentrated alkaloid products with increasingly technical branding and claims about absorption, potency, and formulation.
Some of that technology has legitimate scientific applications worth investigating. However, scientific terminology does not replace evidence of safety, accurate labeling, or reliable manufacturing.
The discovery of MGM-15 in an independently tested Nano Tech tablet illustrates why consumers need more than assurances about product quality.
For individuals who have developed dependence on kratom, concentrated mitragynine, 7-OH, or other opioid-active products, medical treatment offers a more established path forward.
Brooks Healing Center provides comprehensive addiction treatment between Nashville and Chattanooga in Normandy, Tennessee. Our services include medical detox, residential treatment, medication management, PHP, sober living, and continuing recovery support.
If you or someone you love is struggling with these substances, CALL NOW: 931-486-8824 to speak confidentially with our admissions team about treatment options.
You do not need to know every chemical in a product to recognize when dependence has become a problem.
References
Anresco Laboratories. (2026, March 19). Certificate of analysis: 7Stax 80 mg Raspberry Nano Tech tablet, sample 1391007, lot 2026-03. Commissioned by TestMyKratom.org. https://www.testmykratom.org/reports/mit/1391007-7Stax-80mg-Raspberry-Nano-Tech-tablet.pdf
Drug Enforcement Administration. (2026, October 14). Schedules of controlled substances: Temporary placement of 7-hydroxymitragynine and mitragynine pseudoindoxyl above a specified threshold in Schedule I. [Notice of intent]. Federal Register, 91, 65370–65381. https://www.govinfo.gov/content/pkg/FR-2026-10-14/html/2026-20943.htm
Metropolitan Government of Nashville and Davidson County. (2026, July 1). Metro Beer Permit Board reminds businesses of Tennessee kratom ban effective July 1, 2026. https://www.nashville.gov/departments/beer-permits/news/metro-beer-permit-board-reminds-businesses-tennessee-kratom-ban-effective-july-1-2026
National Institute on Drug Abuse. (2026). Phase 1 study of oral MG001 (NCT07204171). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07204171
Sarker, S. D., & Nahar, L. (2025). Formulation and delivery of mitragynine: A mini review. Journal of Medicinal Natural Products, 2(3), 100020. https://doi.org/10.53941/jmnp.2025.100020
U.S. Department of Health and Human Services. (2026, October 9). HHS recommends science-based thresholds to target dangerous enhanced kratom products. https://www.hhs.gov/press-room/hhs-recommends-thresholds-enhanced-kratom-products-7-oh-mgpi.html
U.S. Food and Drug Administration. (n.d.). FDA and kratom. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
7Stax. (n.d.). Nano Tech Mitragynine Tablets (80 mg—1 count). https://7stax.com/products/7stax-nano-tech-mitragynine-tablets-80mg-1-count
